# Synergy of Schweinfurthins with Anti-PD1 Immunotherapy for Melanoma ID# 2018-4724

OH

TTI-4242



#### **TECHNOLOGY READINESS LEVEL** 1-3

### Seeking

Investment | Licensing | Research

### Keywords

CH3

OCH3

- Schweinfurthins
- immunotherapy
- anti-PD-1 antibody
- metastatic melanoma
- advanced stage cancer

#### Researchers

Jeffrey Neighbors Associate Professor **Online Bio** 

**Todd Schell** Professor Website

**Raymond Hohl** Professor Website **Originating College** 

College of Medicine

**Office of Technology Management Contact** 

Douglas Gisewhite drg206@psu.edu 814.865.6961

Derived from Natural Schweinfurthins

## **Technology Summary**

Immune checkpoint inhibitors (ICIs) are undergoing rapid expansion due to growing clinical evidence demonstrating the effectiveness of these agents to improve outcomes for a subset of patients with several difficult to treat and advanced cancers. An adjuvant treatment that would expand the utility of these drugs to treat additional patients would find widespread clinical use. Researchers have demonstrated improved tumor immunity using a novel, small molecule in combination with an anti-PD-1 ICI in a melanoma mouse model where immunotherapy alone fails. The lead compound has potent ICI synergistic effects using a fraction of the maximum tolerable dose administered in short durations without any apparent toxicity.

### **Application & Market Utility**

Melanoma of the skin has the fastest growing incidence rate of all cancers. The annual number of new melanoma cases is slightly over 100,000 in the U.S. and 300,000 worldwide. ICIs are the standard of care for metastatic melanoma. However, despite the tremendous success of ICIs in improving outcomes in advanced-stage cancers, response rates are ~40%, and significant immuno-related side effects occur. New synergistic products are in demand to increase immune response and reduce toxicity.

### Next Steps

Key next steps include: confirm efficacy, tolerability & PK in vivo; validate in vitro tox screen; complete synthesis of 5-10 gram batch (non-GMP); rat and dog dose-ranging & PK studies. Patent pending.



Invent Penn State is a Commonwealth-wide initiative to spur economic development, job creation, and student career success. Invent Penn State blends entrepreneurship-focused academic programs, business startup training and incubation, funding for commercialization, and university-community collaborations to facilitate the challenging process of turning research discoveries into valuable products and services that can benefit Pennsylvanians and humankind. Learn more at invent.psu.edu.

Penn State is an equal opportunity, affirmative action employer, and is committed to providing employment opportunities to all qualified applicants without regard to race, color, religion, age, sex, sexual orientation, gender identity, national origin, disability or protected veteran status.